Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis (EE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00586963|
Recruitment Status : Completed
First Posted : January 7, 2008
Last Update Posted : August 23, 2010
This study is being done to for two reasons:
- To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly.
- To learn about the quality of life changes (good and bad) you may experience with this medication.
|Condition or disease|
|Erosive Esophagitis Reflux Esophagitis GERD|
|Study Type :||Observational|
|Actual Enrollment :||65 participants|
|Official Title:||How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||October 2008|
|Actual Study Completion Date :||December 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586963
|United States, Minnesota|
|Rochester, Minnesota, United States, 55955|
|Principal Investigator:||Yvonne Romero, MD.||Mayo Clinic|